An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening.
Fatima Amanat, Kris M White, Lisa Miorin, Shirin Strohmeier, Meagan McMahon, Philip Meade, Wen-Chun Liu, Randy A Albrecht, Viviana Simon, Luis Martinez-Sobrido, Thomas Moran, Adolfo García-Sastre, Florian Krammer
下载PDF
{"title":"An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening.","authors":"Fatima Amanat, Kris M White, Lisa Miorin, Shirin Strohmeier, Meagan McMahon, Philip Meade, Wen-Chun Liu, Randy A Albrecht, Viviana Simon, Luis Martinez-Sobrido, Thomas Moran, Adolfo García-Sastre, Florian Krammer","doi":"10.1002/cpmc.108","DOIUrl":null,"url":null,"abstract":"<p><p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS-CoV-2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS-CoV-2 in vitro. © 2020 Wiley Periodicals LLC. Basic Protocol 1: Microneutralization assay to test inhibition of virus by antibodies (purified antibodies or serum/plasma) Basic Protocol 2: Screening of anti-SARS-CoV-2 compounds in vitro Support Protocol: SARS-CoV-2 propagation.</p>","PeriodicalId":39967,"journal":{"name":"Current Protocols in Microbiology","volume":" ","pages":"e108"},"PeriodicalIF":0.0000,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361222/pdf/CPMC-58-e108.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/cpmc.108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
引用
批量引用
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS-CoV-2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS-CoV-2 in vitro. © 2020 Wiley Periodicals LLC. Basic Protocol 1: Microneutralization assay to test inhibition of virus by antibodies (purified antibodies or serum/plasma) Basic Protocol 2: Screening of anti-SARS-CoV-2 compounds in vitro Support Protocol: SARS-CoV-2 propagation.
体外微量中和法检测SARS-CoV-2血清学及药物筛选
2019年底，中国湖北省武汉市出现了严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)。从那时起，该病毒在全球传播并引起了大流行。SARS-CoV-2疫苗和药物开发需要能够测量抗体或抗病毒化合物抗病毒活性的检测方法。在这里，我们详细描述了一种微量中和试验，可用于定量评估抗体或药物是否可以在体外阻断SARS-CoV-2的进入和/或复制。©2020 Wiley期刊有限责任公司基本方案1:微量中和试验检测抗体(纯化抗体或血清/血浆)对病毒的抑制作用基本方案2:抗SARS-CoV-2化合物的体外筛选支持方案:SARS-CoV-2传播。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
